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Neuroblastoma (NB) is the most common extracranial solid tumour in infants. Unfortunately, most children present with advanced
disease and have a poor prognosis. In the present study, we evaluated the role of the peroxisome proliferator-activated receptor g
(PPARg) agonist rosiglitazone (RGZ) in two NB cell lines (SK-N-AS and SH-SY5Y), which express PPARg. Rosiglitazone decreased
cell proliferation and viability to a greater extent in SK-N-AS than in SH-SY5Y. Furthermore, 20mM RGZ significantly inhibited cell
adhesion, invasiveness and apoptosis in SK-N-AS, but not in SH-SY5Y. Because of the different response of SK-N-AS and SH-SY5Y
cells to RGZ, the function of PPARg as a transcriptional activator was assessed. Noticeably, transient transcription experiments with a
PPARg responsive element showed that RGZ induced a three-fold increase of the reporter activity in SK-N-AS, whereas no effect
was observed in SH-SY5Y. The different PPARg activity may be likely due to the markedly lower amount of phopshorylated (i.e.
inactive) protein observed in SK-N-AS. To our knowledge, this is the first demonstration that the differential response of NB cells to
RGZ may be related to differences in PPARg transactivation. This finding indicates that PPARg activity may be useful to select those
patients, for whom PPARg agonists may have a beneficial therapeutic effect.
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Thiazolidinediones (TZDs) are a class of molecules, which activate
the nuclear receptor peroxisome proliferator-activated receptor g
(PPARg) (Desvergne and Wahli, 1999) and promote association
with the 9-cis retinoic X receptor (RXR) to form functional
heterodimers that recognise its cognate DNA response element
within target genes (Jude-Aubry et al, 1997; Reginato et al, 1998).
In addition to their well-known effects on glucose homeostasis
(Yki-Ja ¨rvinen, 2004), TZDs have been shown to have anti-
inflammatory (Jiang et al, 1998, Marx et al, 2000) and
antineoplastic effects (Koeffler, 2003, Grommes et al, 2004). The
latter effect is in agreement with the demonstration that PPARg/
RXR signalling exerts an important role in inhibiting cell
proliferation and/or in inducing apoptosis (Grommes et al,
2004). In addition, loss-of-function mutations of the PPARg gene
have been found in human colon and thyroid cancer (Sarraf et al,
1999; Kroll et al, 2000). Therefore, PPARg has been regarded as a
target for anticancer therapy and clinical trials with TZDs for the
treatment of human malignancies involving different organs and
tissues, such as the prostate (Hisatake et al, 2000; Mueller et al,
2000), the colon (Kulke et al, 2002), the breast (Burstein
et al, 2003) and the adipose tissue (Demetri et al, 1999; Debrock
et al, 2003) have been initiated in recent years. Peroxisome
proliferator-activated receptor g is expressed in tumours of the
nervous system, such as astrocytomas, glioblastomas and neuro-
blastomas (Han et al, 2001; Nwako and Robbins, 2001; Strakova
et al, 2004). Neuroblastoma (NB) is the most common extracranial
solid tumour in children and it has a heterogeneous clinical
presentation and course (Shimada and Joshi, 1997). Unfortunately,
most children with NB present with advanced disease. More than
60% of patients with high-risk features will have a poor prognosis
despite intensive therapy. Thus, research efforts to understand the
biologic basis of NB and to identify new and more effective
therapies are essential to improve the outcome for these children.
Retinoids have been shown for instance to interfere with cell
growth and to induce apoptosis in NB cells (Melino et al, 1997,
Voigt and Zintl, 2003) and preliminary clinical trials with retinoids
in NB resulted in improved event-free survival in high-risk
patients, with limited toxic effects (Garaventa et al, 2003; Reynolds
et al, 2003).
The aim of our study was to evaluate the role of the PPARg
agonist rosiglitazone (RGZ) on cell growth, adhesion, invasiveness
and apoptosis in two different NB cell lines (SK-N-AS and
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sSH-SY5Y), which express PPARg (Servidei et al, 2004, Valentiner
et al, 2005). Furthermore, transient transfection experiments with
a peroxisome proliferator response element-luciferase reporter
plasmid were performed, in order to determine whether cell
response to RGZ was related to the level of PPARg transcriptional
activity. Finally, gene sequencing of the PPARg gene was
performed and the amount of expression of PPARg (total and
phosphorylated) was evaluated and correlated to its transcriptional
activity in the two NB cell lines.
MATERIALS AND METHODS
Materials
Human NB cell lines SH-SY5Y and SK-N-AS (American Type
Culture Collection, Manassas, VA, USA) were made available by
the laboratory of Dr CJ Thiele. All the reagents for cell cultures
were from Sigma Chemical Co. (St Louis, MO, USA). Tissue
plastic-ware was from Bibby Sterilin (Staffordshire, UK). Rosigli-
tazone was purchased from Alexis (San Diego, CA, USA).
Cell proliferation
DNA synthesis in NB cells was evaluated by
3[H]-thymidine
incorporation assay. The cells were seeded in 24-well plates and
treated with RGZ for 24 and 48h. During the last 4h, the cells were
pulsed with 1mCi well
13 [H]-thymidine (Amersham Biosciences,
Little Chalfont, Buckinghamshire, UK). Finally, the cells were
washed with PBS and fixed by cold trichloroacetic acid (5% in
distilled water). A 600mlwell
1 portion of extraction buffer (NaOH
0.25 N/SDS 0.1%) was added for 30min at 371C for DNA extraction.
Successively, after pH neutralisation with 6 N HCl, the samples
were analysed by a b-counter (Betamatic V, Kontron Instruments
Ltd, Bletchley, UK). The PPARg antagonist 2,2-bis[4-(glycidyloxy)
phenyl]propane (BADGE, Sigma, Milan, Italy) was used at the
concentration of 20mM and it was added to the cultured cells
30min before RGZ exposure.
For cell proliferation assay, the cells were seeded in six-well
plates. After 24h, the cells were washed with PBS and different
doses of RGZ were added in RPMI medium 1% FBS for 24 or 48h.
Then, the cells were detached (trypsin 0.25%/EDTA) and the cell
number was determined by a haemocytometer.
Cell viability
Cell viability following exposure to different RGZ doses (0.1–
20mM) was determined by MTS assay (Promega Corporation,
Madison, WI, USA), as described previously (Benvenuti et al,
2005). Briefly, the cells were seeded in 96-well plates and exposed
to RGZ for 48h. The assay was then performed according to the
manufacturer’s instructions. The samples were analysed by an
ELISA plate reader (Seac-Radim, Moncalieri, Italy) at 490nm
wavelength. The PPARg antagonist BADGE (Sigma) was used at
the concentration of 20mM and it was added to the cultured cells
30min before RGZ exposure.
Cell adhesion assay
The cells were plated in 96-well plates and different doses of RGZ
(0.1–20mM) were added for 24 and 48h. After washing with PBS,
100ml of Bengal Rose stain (0.25% in PBS) was added to each well
for 5min at room temperature (Gamble and Vadas, 1988). After
aspiration of the stain and washing with PBS, the stain was released
by adding 200ml well
1 of an ethanol/PBS (1:1) solution for
30min. The samples were analysed by an ELISA plate reader (Seac-
Radim) at 570nm wavelength.
Invasion assay
Cell invasion was evaluated using the Chemicon Cell Invasion
Assay (Temecula, CA, USA). The assay is performed in a 24-well
tissue culture plate with 12 cell culture inserts and each Invasion
Chamber insert contains an 8mm pore size membrane over which
a thin layer of extracellular matrix is dried. The cells were
suspended in serum-free medium and RGZ (20mM) was added.
Successively, after rehydration of the insert, the cells were plated in
each Invasion Chamber insert. After 24h, the noninvading cells on
the upper surface of the filter were removed, whereas the invasive
cells were stained with the Cell Stain Solution provided with the
kit, eluted with 150ml insert
1 of 10% acetic acid, transferred onto
a microplate and analysed by an ELISA plate reader (Seac-Radim)
at 540nm wavelength.
Quantitation of matrix metalloproteinase-9 (MMP-9) and
tissue inhibitor of matrix metalloproteinase-1 (TIMP-1)
mRNA
The measurement of MMP-9 and TIMP-1 mRNA was performed
by using a multiplex quantitative real-time RT–PCR method,
based on TaqMan technology, as described previously (Cioppi
et al, 2004). Standard curves for MMP-9 and TIMP-1 mRNAs
consisted of serial 1:10 dilutions from 2.510
7 to 2.510
2fg total
RNA from the fibrosarcoma cell line HT1080 (American Type
Culture Collection).
ELISA assay for MMP-9
Matrix metalloproteinase-9 was measured in conditioned medium
using an ELISA-based commercial kit (Pharmacia, Uppsala,
Sweden), following the manufacturer’s instructions. Matrix me-
talloproteinase-9 can be measured in a range of 1–32ng ml
1, and
the sensitivity of the assay is 0.6ng ml
1.
Immunocytochemistry and flow cytometry analysis for
cleaved caspase 3
The amount of caspase 3 immunoreactive cells was determined as
described previously (Benvenuti et al, 2005). Briefly, the cells were
seeded in chamber slides and exposed to RGZ (20mM). After 48h,
the cells were fixed in paraformaldehyde, then incubated with a
rabbit polyclonal antibody against human cleaved caspase 3 (Asp
175) (Cell Signalling Technology Inc., Beverly, MA, USA) and
subsequently with a biotinylated secondary antibody. The reaction
product was visualised by ABC peroxidase-based detection
protocol and AEC kit (Vectastain ABC kit, Vector Laboratories
Inc., Burlingame, CA, USA). Finally, the cells were counterstained
with haematoxylin and apoptotic cells/field were counted in 10
fields (40).
Moreover, cleaved caspase 3 was evaluated by flow cytometry,
which was performed as described previously (Carloni et al, 1998).
Briefly, the cells were seeded onto 100mm Petri dishes at the
density of 310
6cells and incubated for 24h in complete medium.
Then, RGZ (20mM) was added and the cells were incubated at 371C
in humidified atmosphere (5% CO2/95% air). After 48h, the cells
were detached (trypsin 0.25%/EDTA) and fixed with 3% paraf-
ormaldehyde in distilled H2O for 10min at 371C. After permea-
bilisation in ice-cold 90% methanol, the cells were incubated with a
rabbit polyclonal antibody against cleaved caspase 3 (Asp 175)
(Cell Signalling Technology) or with a nonspecific IgG as control at
the appropriate dilution (1:25) in Incubation Buffer (BSA 0.5% in
PBS 1). Subsequently, the cells were washed with Incubation
Buffer and incubated with a FITC-conjugated goat anti-rabbit
secondary antibody (1:100) (Southern Biotechnology Associates
Inc., Birmingham, AL, USA) for 30min. FITC green fluorescence
was detected at 515–555nm using a FL-1 detector of a FACScan
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sflow cytometer (Becton Dickinson, Mountain View, CA, USA)
equipped with a 15mW argon-ion laser for excitation. Debris were
gated out by establishing a region around the population of
interest on the Forward Scatter vs Side Scatter dot plot. For each
sample, 10000 events in the region of interest were recorded at a
flow rate of 200–300cells/s
1. Data were processed with analysis
software LYSYS II (Becton Dickinson).
Transient transfection of NB cells
In order to determine the activity of PPARg in NB cells, the cells
were transfected at the density of 410
6cells (SK-N-AS) and
210
6cells (SH-SY5Y) in 100-mm dishes with 2mg peroxisome
proliferator response element (adipocyte response element)-73-tk-
luciferase reporter plasmid (containing three copies of the
peroxisome proliferator response element from the adipocyte lipid
binding protein gene ligated to a herpes simplex thymidine kinase
promoter upstream from a luciferase gene), 0.15mg of human
PPARg expression plasmid, and 1mg pSV2CAT (a vector contain-
ing Simian virus 40 early promoter and enhancer sequences that
drives a chimeric chloramphenicol acetyl transferase gene) as an
internal control by calcium phosphate precipitation, as described
previously (Ferruzzi et al, 2005). Twenty-four hours after
transfection, the cells were treated with RGZ. Twenty-four hours
later, the cells were harvested, washed twice with PBS and lysed.
Fifty microlitres of cell extract was incubated with luciferase assay
reagent based on the original protocol by de Wet et al (1987). The
number of relative light units with a 3-s delay and a 30-s
incubation was measured using a Sirius1 luminometer (Berthold
Detection System, Pforzheim, Germany). Chloramphenicol acetyl
transferase activity was measured as described previously (Crabb
and Dixon, 1987). The conversion of chloramphenicol to its
acetylated products was quantified on a b-scanner (Ambis System,
San Diego, CA, USA).
Sequence analysis of the PPARc gene
Genomic DNA was extracted from cell cultures using the
automated DNA extraction system Biorobot EZ1 Workstation
(Qiagen, Crawley, W Sussex, UK). The entire coding region of the
PPARg gene and the exon–intron boundaries were amplified by
PCR, using primers sequences and PCR conditions as described
previously (Costa-Guda et al, 2005). Amplicons were purified
using the QIAquick purification kit (Qiagen) and direct sequencing
was carried out using the Big Dye Terminator v1.1 Cycle
Sequencing kit (Applied Biosystems, Warrington, Cheshire, UK),
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Figure 1 (A and B) Effect of a 24- or a 48-h treatment with RGZ on
3[H]thymidine incorporation in SK-N-AS (A) and SH-SY5Y (B) cells. *Po0.05 vs
control untreated cells (C). (C and D) Effect of a 24- or a 48-h treatment with RGZ on SK-N-AS (C) and SH-SY5Y (D) cell proliferation. *Po0.05 vs
control untreated cells (C).
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saccording to the manufacturer’s instructions. Sequencing reactions
were purified using the DyeEx 2.0 Spin kit (Qiagen) and samples
were run on an ABI 310 capillary sequencer (Applied Biosystems).
Western blot analysis of PPARc expression
The NB cells were washed and resuspended in lysis buffer. In
addition, the human adenocarcinoma cell line PANC-1 and HPAC
(American Type Culture Collection) were used as the positive and
negative control for PPARg expression, respectively (Galli et al,
2004). After protein measurement (Coomassie kit, Bio-Rad
Laboratories, Hercules, CA, USA), 30mg of protein was diluted in
2 Laemmli’s reducing sample buffer, incubated at 951C for 5min
and loaded onto a 10% polyacrylamide-bisacrylamide gel. After
SDS–PAGE, proteins were electroblotted into nitrocellulose
(Sigma Chemical Co.). Equivalent protein loading was verified by
staining parallel gels with Coomassie R. After blocking in 5%
skimmed milk for 2h, nitrocellulose membranes were washed and
then immunostained with a rabbit anti-human PPARg antibody
(1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
followed by a secondary anti-mouse IgG antibody (1:2000) (New
England Biolabs, Beverly, MA, USA). The antibody-reacted
proteins were revealed by LumiGLO chemiluminescent reagent
and peroxide (New England Biolabs).
PPARc phosphorylation assay
Protein extraction was performed by boiling the cell pellet in 10%
glycerol, 2% SDS and 50mM Tris-HCl (pH 7.5) for 10min. The
lysate was diluted 1:10 with RIPA-like buffer containing 50mM
Tris-HCl (pH 7.5), 1% Triton X-100, 0.5% sodium deoxycholate,
150mM NaCl, 5mM EDTA, 25mM b-glycerophosphate, 1mM
Na3VO4, 100mM PMSF, supplemented with Complete Protease
Inhibitor Cocktail (Roche Applied Science, Milan, Italy). SDS was
then added to achieve a final concentration of 1% and
immunoprecipitation was performed with a rabbit anti-human
PPARg antibody (1:100) (Santa Cruz Biotechnology) at 41C, for
3h. Immunocomplexes were recovered by incubation with
Protein-A Sepharose (Sigma) for additional 16h at 41C. The
immunocomplexes were then dissociated by boiling for 5min in
Laemmli’s buffer, the beads were collected by centrifugation and
SDS–PAGE was performed with the supernatant. The protein were
electroblotted to nitrocellulose transfer membrane Protean (What-
man, VWR International, Milan, Italy) and were detected by
incubating the filter with the anti-PPAR-g antibody or with an
anti-phosphoserine mouse monoclonal antibody (1:400) (clone
PSR-45, Sigma) followed by a secondary anti-rabbit IgG (1:2000)
or anti-mouse IgG (1:2000) antibody, respectively (Amersham
Biosciences). Detection of the protein bands was performed using
the Amersham ECL plus Kit (Amersham Biosciences).
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Figure 2 (A and B) Role of RGZ on SK-N-AS (A) and SH-SY5Y (B) cell viability, as assessed by MTS assay (see Materials and Methods). *Po0.05 vs
control untreated cells (C). (C and D) Effect of different concentrations and time of exposure to RGZ (24 or 48h) on SK-N-AS (C) and SH-SY5Y (D) cell
adhesion, as assessed by Bengal Rose assay (see Materials and Methods). *Po0.05 vs control untreated cells (C).
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sStatistical analysis
All the experiments were carried out in triplicate or esaplicate and
were repeated at least three times. Data were expressed as
mean7s.e. Statistical differences were analysed using one-way
analysis of variance. Significance was adjusted for multiple
comparisons of means using Bonferroni’s approximation.
RESULTS
Effects of RGZ treatment on cell proliferation
The effects of RGZ on
3[H]-thymidine incorporation in the two NB
cell lines SK-N-AS and SH-SY5Y are reported in Figure 1. In SK-N-
AS (Figure 1A), a significant reduction of DNA synthesis was
determined by exposure to RGZ (1–20mM) for 24 and 48h,
whereas in SH-SY5Y (Figure 1B), this effect was observed only
after a 48-h exposure.
With regard to cell counts, a significant antiproliferative effect
was observed following a 24- or 48-h treatment with RGZ (10
and 20mM) in SK-N-AS (Figure 1C). In SH-SY5Y, a significant
reduction of the cell number was observed only after a 48-h
treatment with 20mM RGZ (Figure 1D), although to a lower extent
than in SK-N-AS. Only a higher concentration of RGZ (80mM) was
able to determine in SH-SY5Y a reduction of the cell number
(54.471.3%, mean7s.e. vs untreated cells, considered as 100%)
similar to the decrease determined by the same dose of RZG in
SK-N-AS (57.971.4%) (data not shown).
Effects of RGZ on cell viability and adhesion
The effect of RGZ on NB cell viability is shown in Figure 2A and B.
In SK-N-AS, cell viability was significantly reduced after a 48-h
exposure to RGZ (0.1–20mM) and 20mM RGZ determined the
maximal inhibition (54%) (Figure 2A). In SH-SY5Y cells, RGZ
(0.1–20mM) was also able to reduce cell viability, but the decrease
was limited to 13% (20mM RGZ) (Figure 2B).
Moreover, the effect of RGZ on cell adhesion was determined.
Interestingly, in SK-N-AS cells RGZ significantly induced an
inhibition of cell adhesion, which was already present after 24h of
incubation at the concentration of 10 and 20mM (Figure 2C). After
a 48-h treatment, a significant inhibitory effect was already present
at a lower dose (5mM). Conversely, in SH-SY5Y cells no inhibitory
effect was observed for all the tested RGZ concentrations, neither
after a 24-h nor after a 48-h exposure (Figure 2D).
Effects of the PPARc antagonist BADGE on cell
proliferation and viability
In order to determine whether the effects of RGZ on cell
proliferation and viability were truly mediated by PPARg,
additional experiments were performed in SK-N-AS using the
PPARg antagonist BADGE. The exposure to 20mM BADGE did not
determine any effect both on
3[H]-thymidine incorporation and on
cell viability, thus indicating that at this concentration this
compound had no toxic effect. The same concentration of BADGE
was able to revert the inhibitory effect of 20mM RGZ on
3[H]-
thymidine incorporation (Figure 3A) as well as on cell viability
(Figure 3B).
Effect of RGZ on cell invasiveness and on the expression of
MMP-9/TIMP-1
The effect of RGZ (20mM) on the invasiveness ability of NB cells
was determined. When SK-N-AS cells were tested, the number of
invasive cells markedly decreased after RGZ exposure. A
representative example is shown in Figure 4A and B. At variance
with SK-N-AS, no effect was observed in SH-SY5Y (not shown).
These results were quantitatively confirmed by spectrophoto-
metric analysis on extracts from stained cells eluted from the
membrane invasion chamber (Figure 4C).
Moreover, in both cell lines the effect of different doses of RGZ
(1, 10 and 20mM) on the expression of MMP-9 and of its specific
tissue inhibitor TIMP-1 was investigated. In untreated SK-N-AS
cells, the amount of MMP-9 mRNA, as assessed by real-time
RT–PCR, was 12.0371.9710
3fg 25ng total RNA
1 (mean7s.e.).
Rosiglitazone (10 and 20mM) significantly decreased the level of
MMP-9 transcript (Figure 5A). Accordingly, the amount of protein
was significantly reduced by RZG in a dose-dependent manner
(Figure 5B). In SH-SY5Y cells, no MMP-9 transcript was detectable
(data not shown). As per TIMP-1 expression, the amount of mRNA
in untreated cells was 6.9370.6710
7fg 25ng total RNA
1 in SK-
N-AS and 6.470.210
6 fg25ng total RNA
1 in SH-SY5Y cells.
Rosiglitazone did not determine any significant variation, although
a trend towards an increase was observed in SK-N-AS (Figure 5C).
Altogether, these results suggest that RGZ effectively counteracts
cell invasiveness in SK-N-AS, but not in SH-SY5Y cells.
Effects of RGZ on apoptosis
In order to determine whether RGZ is also able to induce apoptosis
in the two NB cell lines used in this study, the number of cells
showing positivity for cleaved caspase 3 was evaluated by
immunocytochemistry. In SK-N-AS, the amount of apoptotic cells
in untreated samples was 0.4470.23% (mean7s.e.), whereas RGZ
treatment (20mM) significantly increased the number of caspase
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Figure 3 Role of the PPARg antagonist BADGE (indicated as B) (20mM)
in counteracting the effect on
3[H]thymidine incorporation (A) and on cell
viability (B) induced by 20mM RGZ in SK-N-AS cells. *Po0.05 vs control
untreated cells (C).
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s3-positive cells (2.1270.24%, Po0.05). In SH-SY5Y, there was no
difference in the amount of cleaved caspase 3-positive cells in
untreated vs RGZ-treated samples (0.4370.13 vs 0.4970.11%,
respectively, P40.05). Representative examples are shown in
Figure 6. Several immunostained SK-N-AS cells were present after
exposure to RGZ (Figure 6B), compared to the absence of staining
in untreated cells (Figure 6A). In contrast, only a very few SH-
SY5Y cells showed positivity for cleaved caspase 3 either before
(Figure 6C) or after (Figure 6D) RGZ treatment. The effect of
treatment with RGZ (20mM) on caspase 3 activation in SK-N-AS
was confirmed by flow cytometry analysis. After labelling activated
caspase 3, treated cells showed a shift to higher values of
fluorescence, when compared to control cells (9.73, treated vs
8.28, control, median values of fluorescence histograms). Con-
versely, no effect was observed in SH-SY5Y (8.51 treated, vs 8.48,
control, median values of fluorescence histogram) (data not
shown).
PPARc activity in NB cells
Because of the different response to RGZ, PPARg activity was
determined in SK-N-AS and SH-SY5Y cells. Peroxisome prolif-
erator-activated receptor g activity was investigated by transient
transfection assay and PPARg transactivation was monitored by
the activity of transfected adipocyte response element-73-tk-
luciferase reporter cells. In SK-N-AS, RGZ treatment (20mM)
induced a near three-fold increase of the reporter activity
compared to untreated control cells (Figure 7). Conversely, no
effect was observed in SH-SY5Y after RGZ exposure. Transfection
of NB cell lines with a human PPARg expression plasmid
stimulated the reporter activity about 1.5- and eight-fold over
the control in SK-N-AS and SH-SY5Y, respectively. Furthermore,
the treatment of PPARg-transfected cells with RGZ caused an
additional five- and 17-fold increase of the reporter activity in the
two cell lines, respectively.
PPARc gene sequencing and expression in NB cells
In order to determine whether the different function of PPARg as a
transcriptional activator in the two NB cell lines was due to gene
mutations, sequence analysis of the entire coding region of the
PPARg gene was performed. However, no mutation was found in
either SH-SY5Y or SK-N-AS. Similarly, no evident difference in the
amount of expression of PPARg protein was observed between the
two cell lines, as assessed by Western blot analysis (Figure 8A).
Equivalent protein loading was verified by staining parallel gels
with Coomassie R, as shown in Figure 8B. Because there is
evidence that PPARg phosphorylation reduces the activity of the
receptor (Shao and Lazar, 1999), PPARg immunoprecipitation was
performed, followed by SDS–PAGE and Western blot analysis
using either an anti-PPARg or an anti-phosphoserine monoclonal
antibody. Interestingly, the amount of phosphorylated PPARg was
found to be markedly lower in SK-N-AS, thus suggesting that the
higher PPARg activity in this cell line compared to SH-SY5Y may
be due to a different phosphorylation status of the receptor
(Figure 8C).
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Figure 4 Role of RGZ on SK-N-AS cell invasiveness. (A) Untreated control cells. (B) Cells treated with 20mM RGZ for 24h. The invasive cells on the
lower surface of the membrane were stained with crystal violet (see Materials and Methods). (C) Spectrophotometric analysis on extracts from stained cells
eluted from the membrane invasion chamber. *Po0.05 vs control untreated cells (C).
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sDISCUSSION
In the present study, the effect of the PPARg ligand RGZ on two NB
cell lines, which have a stromal (S) (SK-N-AS) and a neuroblast (N)
(SH-SY5Y) phenotype (Ciccarone et al, 1989; Ross et al, 2003;
Servidei et al, 2004), was addressed. We first demonstrated that cell
proliferation was readily inhibited by RGZ in the S-type cell line,
whereas this effect was less evident in the N-type cells. Cell viability
was significantly reduced by RGZ in both cell lines, although a
much stronger maximal inhibition was observed in SK-N-AS. The
effects of RGZ on cell proliferation and viability were readily
counteracted by the PPARg antagonist BADGE, thus indicating
that PPARg activation has an important role in eliciting these
biological effects. Furthermore, the capability of cultured cells to
adhere to a solid substrate in response to RGZ was assessed. In
fact, cell adhesion assay is an indicator of cell spreading and
adhesion molecules play a critical role in promoting the processes
leading to tumour invasion and metastasis (Cavallaro and
Christofori, 2004). Again, we found that RGZ readily decreased
SK-N-AS cells adhesion starting from a 24-h exposure (10 and
20mM), whereas it had no effect on SH-SY5Y cells, even after a 48-h
treatment. As an additional feature of malignant behaviour, cell
invasiveness was determined. Rosiglitazone effectively reduced the
passage of the S-type cells, but not of the N-type cells, through the
extracellular matrix-coated membranes. Therefore, altogether
these results provide evidence that RGZ acts as an effective
inhibitor of cell proliferation, adhesion and invasiveness in SK-N-
AS, but not in the SH-SY5Y NB cell line.
It has to be mentioned that the inhibitory effect of RGZ on SK-
N-AS cell invasiveness might be partially PPARg-independent.
With regard to this point, the activity of MMPs, which promote the
invasion of the extracellular matrix by tumoral cells, has been
related to the progression of a variety of tumours, including NB
(Sugiura et al, 1998; Chantrain et al, 2004). Accordingly, MMPs
have been addressed as a target for cancer therapy (Overall and
Kleifeld, 2006). RZG has been shown for instance to reduce the
expression/activity of MMPs in a PPARg-independent manner in
adrenal (Ferruzzi et al, 2005) and pancreatic tumour cells (Farrow
et al, 2003; Galli et al, 2004) and to increase the expression of
TIMP-1 in breast cancer cells (Liu et al, 2003). In SK-N-AS, but not
in SH-SY5Y, RGZ significantly reduced the amount of MMP-9,
whereas the expression of the MMP inhibitor TIMP-1 showed a
small but not statistically significant increase at higher levels. The
demonstration that the proliferation of embryonic stem cells with a
null mutation for PPARg could be inhibited by glitazones
(Palakurthi et al, 2001), which were also able to differentiate these
cells into macrophages (Chawla et al, 2001), further supports the
presence of PPARg-independent mechanisms of agonist action.
Furthermore, in our study the role of RGZ in inducing apoptosis in
NB cells was addressed. Interestingly, very recently apoptosis has
been indicated as a surveillance mechanism against metastases
in NB (Stupack et al, 2006). In fact, it has been shown that
suppression of caspase 8 expression occurs during the develop-
ment of NB metastases in vivo, whereas reconstitution of caspase 8
expression potentiated apoptosis and counteracted the spreading
of tumour cells. Peroxisome proliferator-activated receptor g
agonists induce apoptosis in different cell types and in most
studies it has been shown that caspase 3 plays an important role in
mediating apoptotic death (Grommes et al, 2004). We found that
RGZ (20mM) increased the amount of cleaved (i.e. activated)
caspase 3 only in SK-N-AS cells. However, both immunocyto-
chemistry and flow cytometry experiments did not show a very
strong apoptotic effect of RZG, thus suggesting that RGZ does not
appear to play a major role in stimulating apoptosis in these NB
cells. These results are partially in agreement with a previous
report, in which RGZ (up to 50mM) was not able to induce
apoptosis in different NB cell lines, although SK-N-AS cells were
not evaluated (Servidei et al, 2004).
The different response of SK-N-AS and SH-SY5Y cells to RGZ
appeared to be due to the function of PPARg as a transcriptional
activator, which was readily demonstrated in SK-N-AS but not
in SH-SY5Y, as assessed by transient transfection with a PPARg
responsive element. This difference might be due to a mutation of
the PPARg gene. No mutation in exons 3 and 5, the biologically
important regions for DNA and ligand binding of PPARg,
respectively, has been detected previously in the two NB cell lines,
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Figure 5 Amount of MMP-9 mRNA (A) and protein (B) and of TIMP-1
mRNA (C) in SK-N-AS cells in the absence or in the presence of different
concentrations of RGZ. *Po0.05 vs control (indicated as C).
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swhich were used in our study (Servidei et al, 2004). A K422Q
mutation has been described previously in exon 6 of PPARg in
colon cancer cell lines, but it did not alter ligand-induced
transactivation (Gupta et al, 2003). Nevertheless, we sequenced
the entire coding region of the PPARg gene in SK-N-AS and in SH-
SY5Y and no mutation was found. Only when SH-SY5Y cells were
transfected with a human PPARg expression plasmid, the response
to RGZ was effectively elicited, thus confirming that the lack of
SK-N-AS
SH-SY5Y
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CD
Figure 6 Immunocytochemistry for the detection of cleaved caspase 3-positive cells. (A and C) Control untreated cells (SK-N-AS and SH-SY5Y,
respectively). (B and D) RGZ-treated cells (SK-N-AS and SH-SY5Y, respectively). Magnification 40.
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Figure 7 PPARg transcriptional activity in control untreated NB cells (C),
in cells treated with RGZ (20mM) and in cells transfected with PPARg in the
absence or in the presence of RGZ. L/C: peroxisome proliferator response
element-n73-tk-luciferase reporter activity, normalised for CAT activity.
*Po0.05 vs C. **Po0.05 vs PPARg transfected cells in the absence of
RGZ.
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Figure 8 (A) Western blot analysis of the amount of PPARg in SK-N-AS
and SH-SY5Y. PANC-1 and HPAC cells (human pancreatic adenocarci-
nomas) were used as the positive and negative control, respectively. (B)
Coomassie R-stained gel, showing equal protein loading of the same
samples indicated in A. (C) Detection of total (anti-PPARg antibody) and
phosphorylated (anti-P-Ser antibody) PPARg, after PPARg immunopreci-
pitation.
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sresponse was truly due to the very low transactivation potential of
the endogenous PPARg. It has to be mentioned that the
phosphorylated status of PPARg is important in determining its
transcriptional activity. In fact, there is evidence that PPARg
phosphorylation reduces the activity of the receptor (Shao and
Lazar, 1999). We performed Western blot analysis of total and
phosphorylated PPARg and we found that the amount of the
phosphorylated form was markedly lower in SK-N-AS than in SH-
SY5Y. This finding indicates that the lower activity of PPARg in the
latter NB cell line may be likely due to a different phosphorylation
status of the receptor. In addition, it might be hypothesised that
PPARg overexpression in transfected SH-SY5Y cells might increase
the level of unphosphorylated PPARg beyond a critical threshold,
thus eliciting transcriptional activity. Other recent studies have
shown variable antineoplastic effects of PPARg agonists in NB cell
lines expressing PPARg (Han et al, 2001, Servidei et al, 2004,
Valentiner et al, 2005), but the activity of PPARg was addressed
only in one study, in which PPARg was found to be functionally
active in different cell lines and particularly in SK-N-AS (Servidei
et al, 2004). However, the relationship between PPARg transactiva-
tion and the response to TZDs was not addressed. Thus, our study
extends the work of other authors, because the different response
of NB cells to TZDs was related for the first time to differences in
PPARg transactivation, which, in turn, appear to be due to a
different phosphorylation status of the receptor.
Our original results, if confirmed in different cell models, might
also open a window on potential prognostic and therapeutic
applications, based on PPARg and PPARg ligands. The presence in
the tumour tissue of a transcriptionally active PPARg might for
instance be useful to select those patients, for whom TZDs might
be beneficial. In fact, although some of the effects of TZDs may be
PPARg-independent, as mentioned previously, admittedly most of
them are dependent on the presence of a transcriptionally active
PPARg. The low toxicity demonstrated by RGZ as an antidiabetic
agent (Yki-Ja ¨rvinen, 2004) and the fact that the inhibitory effects
on cell proliferation, adhesion and invasiveness were present in
our study at concentrations similar to those achieved in vivo (Cox
et al, 2000) are additional important points to be raised in favour
of the possible use of this drug in NB.
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